Kornimate/medical-research-clean huggingface dataset:
an investigational immuno-therapy trial of pomalidomide and low-dose dexamethasone with or without elotuzumab to treat refractory and relapsed and refractory multiple myeloma (eloquent-3)

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine if adding elotuzumab to pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination * documented refractory or relapsed and refractory multiple myeloma * refractory to proteosome inhibitor and lenalidomide, and to last treatment * relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment * measurable disease at screening * eastern cooperative oncology group (ecog) performance status ≤ 2 exclusion criteria: * active plasma cell leukemia * prior treatment with pomalidomide * unable to tolerate thromboembolic prophylaxis while on the study * prior autologous stem cell transplant within 12 weeks * known human immunodeficiency virus (hiv) infection or active hepatitis a, b, or c
a study of tirzepatide (ly3298176) in chinese participants without type 2 diabetes who have obesity or overweight (surmount-cn)

Conditions: Obesity; Overweight; Metabolism and Nutrition Disorder

Summary: this is a study of tirzepatide in chinese participants without type 2 diabetes who have obesity or overweight. the main purpose is to learn more about how tirzepatide affects body weight.


Eligibility criteria:
inclusion criteria: * have a bmi ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * have a history of at least one self-reported unsuccessful dietary effort to lose body weight exclusion criteria: * have diabetes mellitus * have a self-reported change in body weight \>5 kg within 3 months prior to screening * have obesity induced by other endocrinological disorders * have had a history of chronic or acute pancreatitis * have a history of significant active or unstable major depressive disorder (mdd) or other severe psychiatric disorder within the last 2 years * have any lifetime history of a suicide attempt * have a family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2)
metformin treatment before in vitro fertilization (ivf) in women with ultrasound evidence of polycystic ovaries

Conditions: Polycystic Ovary Syndrome

Summary: the aim of study was to investigate whether pre-treatment with metformin before and during ivf increases the live birth rate compared to placebo in women with sonographic evidence of polycystic ovaries (pco), but without any clinical manifestations of polycystic ovary syndrome (pcos).


Eligibility criteria:
inclusion criteria: * women attending with ovulatory pco due to undergo ivf/icsi treatment. * first or second cycle of ivf/icsi. * if previously on metformin, a minimum one month washout period was required. * polycystic ovaries diagnosed by ultrasound presence of ≥12 follicles measuring 2-9 mm in diameter in at least one ovary and/or increased ovarian volume (≥10 ml). * written informed consent. exclusion criteria: * clinical manifestations of pcos, including any of the following: 1. oligo- or amenorrhoea with cycles ≥42 days apart. 2. anovulation with mid-luteal progesterone \<16 nmol/l. 3. biochemical hyperandrogenism with serum testosterone ≥3.5 nmol/l and/or free androgen index \>5 (fai = \[total testosterone/shbg\] x 100). 4. clinical hyperandrogenism with hirsutism or acne requiring treatment at least weekly. * age \>38 years. * bmi \>35 kg/m2. * basal fsh \>12 iu/l. * liver disease or alt \>80 iu/l. * renal disease, or creatinine \>130 nmol/l. * alcoholism or drug abuse. * diabetes mellitus (evaluated by fasting glucose \>6.7mmol/l). * per oral steroid treatment in last month. * cimetidine, anticoagulation, erythromycin, or other macrolides in last month. * hyperprolactinemia (prolactin \>700 miu/l). * abnormal thyroid function tests (tsh outside of laboratory normal range). * congenital adrenal hyperplasia.

Keywords: polycystic ovaries ovarian stimulation ivf ovarian hyperstimulation metformin
ultrasound vs nerve stimulation - why is a pns so effective?

Conditions: Musculoskeletal Pain

Summary: the traditional model of localizing a nerve for blockade is using a peripheral nerve stimulator, pns. recent advances in ultrasound technology has allowed ultrasound to guide nerve blockade. however despite excellent visualization nerve block success has not significantly improved. i aim to show that this is because the pns stimulation of a nerve is more than a proximity response as thought but a correct fascial plane response and hence the high success rate of this blind approach.


Eligibility criteria:
inclusion criteria: * asa 1 to 3 patients for any shoulder surgery or unilateral acl knee surgery exclusion criteria: * refusal to consent * allergy to chirocaine local anaesthetic * pace maker in situ * sepsis at site of regional block
acute achilles tendon rupture - choice of treatment based on ultrasound findings

Conditions: Achilles Tendon Rupture; Athletic Injuries; Ultrasonography; Rupture; Acute Disease

Summary: patients with acute achilles tendon rupture will go through an acute ultrasound. based on the distance between the ends of the tendon the investigators will decide if the patient is going to be treated with or without surgery.


Eligibility criteria:
inclusion criteria: * acute achilles tendon rupture diagnosed less than 48 hours from injury * mid-substance rupture exclusion criteria: * previous achilles tendon rupture * lower leg disability * diabetes mellitus * neurovascular disease * immunosuppression * non-swedish speaker
omega-3 fatty acid status in morbid obesity before and after surgical treatment

Conditions: Morbid Obesity; Cardiovascular Disease; Fatty Acid Levels

Summary: the purpose of this study is to determine the concentration of omega-3 fatty acids in plasma, blood and abdominal fat before and after bariatric surgery to provide guidance for future studies.

the omega-3 fatty acids are essential for human growth, development and well-being. numerous studies have shown that a relatively high intake of the omega-3 fatty acids are beneficial in brain and visual development, psychiatric disorders, rheumatic disorders, inflammatory responses and cardiovascular disease. as an example, low levels of tissue omega-3 fatty acids are associated with a markedly higher rate of death from cardiac causes compared to patients with relatively high concentrations of the omega-3 fatty acids. obese patients often have an unhealthy dietary intake and evidence of increased inflammatory processes. after a gastric bypass patients will have decreased absorption of fats from the gastrointestinal tract and may become fatty acid deficient. while gastric bypass may decrease death from cardiovascular disease in morbidly obese patients, cardiovascular disease is still the most common cause of death after a gastric bypass. there are numerous nutritional deficiencies which occur after gastric bypass and many of these are well documented. however, there are no data concerning the plasma and tissue levels of omega-3 fatty acids in morbidly obese patients either before or after operation.

Eligibility criteria:
inclusion criteria: * surgical group candidates must be undergoing surgery for morbid obesity, abdominoplasty or other abdominal operation. * must have adequate venous access. exclusion criteria: * insufficient venous access

Keywords: morbid obesity omega-3 fatty acid levels
effects of tdcs on heart rate variability in chronic low back pain

Conditions: Chronic Low-back Pain

Summary: chronic low back (clbp) pain is an important public health and socioeconomic problem worldwide and, despite the volume of research in the area, it remains a difficult condition to treat. there are some evidences that altered heart rate variability (hrv) parameters are associated with different clinical disorders, such as chronic low back pain. for instances, diminished parasympathetic activity has been explored as a potential therapeutic target. considering the dynamic interaction between brain and heart, neuromodulatory strategies targeting this relationship could exert a positive influence on cardiac autonomic system and pain modulation systems. transcranial direct current (tdcs) stimulation is a noninvasive neuromodulation technique that has been presenting recent advances in the treatment of chronic pain. however, tdcs application focusing on brain-heart interaction has not been extensively explored, especially on chronic pain conditions. this study aims to investigate the effects of tdcs on hrv in chronic low back pain patients. sixty patients will be randomized into two distinct groups to receive either tdcs (anodal) or tdcs (sham) in a single session protocol. the primary clinical outcome (hrv parameter) will be collected before, during and post-tdcs. the data will be collected by a blind examiner to the treatment allocation.


Eligibility criteria:
inclusion criteria: * complaining of back pain for more than three months. * presence of a chronic pain measurable with the number rating scale (nrs 0-10) not less than 4 during a 1 week daily nrs monitoring. * seeking care for low back pain. exclusion criteria: * previous surgery on the spine * spondylolisthesis * previous treatment with tdcs * disc herniation with nerve compression neurological * psychiatric * rheumatologic diseases * impaired sensibility * use of pacemakers or other implanted devices * pregnancy * cardiovascular diseases
prospective multidisciplinary post-covid-19 registry tyrol

Conditions: Post COVID-19 Condition

Summary: longitudinal, prospective observational cohort study enrolling patients with persisting symptoms (\> 12 weeks) after covid-19 in a multidisciplinary care model.

post-covid-19 syndrome comprises a set of persistent physical, cognitive and/or psychological symptoms that continue for more than 12 weeks after illness and are not attributable to alternative diagnoses. as these symptoms may manifest in all covid-19 severity grades, even in patients with mild or moderate disease, there is an urgent need for resource allocation in the health care system and accompanied research proposals to understand disease phenotypes and clinical trajectories. with this prospective multidisciplinary registry, the investigators aim to establish a clinical and researchbased system by providing optimized medical diagnostic and therapeutic approaches in a model region in austria (tyrol).

Eligibility criteria:
inclusion criteria: * individuals with persistent post covid symptoms ≥ 12 weeks * post covid functional status scale (pcfs) ≥ 2 exclusion criteria: * observation time after infection \< 12 weeks * pcfs \< 2

Keywords: post covid-19 syndrom long covid long term sequelae
high intensity interval training in chronic stroke

Conditions: Chronic Stroke

Summary: both gait and cardiovascular dysfunction are primary factors limiting community ambulation for stroke individuals. increased gait variability and asymmetry contributes to a higher risk of falls, leading to reduced physical activity, decreased cardiorespiratory endurance, and increased walking economy and sympathetic nervous system activity, thereby potentially triggering secondary strokes. previous studies have primarily focused on the significant improvements in walking endurance and speed with high-intensity interval training (hiit) on a treadmill, leaving a gap in understanding the effects of hiit on oxygen uptake efficiency slope (oues) and gait quality for stroke individuals using a stationary bicycle ergometer with exergaming. therefore, this study aims to investigate the effects of hiit using a stationary bicycle ergometer on improving cardiorespiratory fitness and gait quality in individuals with chronic stroke.


Eligibility criteria:
inclusion criteria: * aged 18-69 years * at least 6 months post-stroke * functional ambulation category (fac) ≥ 3 * mini-mental state examination (mmse) ≥ 24 * able to walk 10 meters overground with or without assistive devices exclusion criteria: * unstable cardiopulmonary conditions within the last 3 months * other chronic neurological disorders * contraindications to exercise as recommended by the american college of sports medicine (acsm) * severe lower limb spasticity (modified ashworth scale \> 2 points) * implanted pacemaker or cardioverter defibrillator

Keywords: high-intensity interval training cardiorespiratory fitness gait quality chronic stroke
efficacy of zingiber officinalis (homoeopathic medicine) in treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: acne is one of the most common skin problems in teenagers and adolescents. there are many lesser known homoeopathic medicines which have been mentioned in the literature for treatment of acne but their potential has not been properly assessed /documented and therefore these medicines don't form a part of many prescriptions. as a part of this study, efficacy of zingiber officinalis will be studied in the treatment of acne vulgaris


Eligibility criteria:
inclusion criteria: * males and females between 12 to 25 years of age * presence of inflammatory and non-inflammatory lesions * able to follow-up according to protocol * patients not taking any medication for treatment of acne in preceding one month. exclusion criteria: * acne conglobata * pregnant or breast feeding females or females having intention of becoming pregnant * significant systemic disease * any drug/ alcohol addiction * history of chronic diseases treated with medications in the preceding month which might affect acne condition and treatment outcome

Keywords: acne vulgaris homoeopathy zingiber officinalis
a kynurenine pathway-based molecular imaging study of individualized diagnosis and treatment for major depressive disorder

Conditions: Major Depressive Disorder

Summary: major depressive disorder (mdd) is a chronic disease with high incidence rate, high recurrent rate and need whole course medical management. varied clinical symptoms and unclear pathogenesis cause a series of clinical problem, such as low diagnostic rate and low effective treatment rate. based on neuroimmune mechanisms of mdd, our previous study indicates that kynurenine pathway (kp) in serum may be the connections between central immune and peripheral immune, that key factors of kp may change the brain structure and function through affecting the central immune. the core research issue of this project are the inherent associations between metabonomics of inflammatory factors in kp, clinical phenotypes of mdd, and neuroimaging features. this project will focus on first-episode mdd, mass spectrometry analysis of kp factors will be conducted first, also multi-modal neuroimaging techniques will be applied to detect topological characteristics of brain structure and function in mdd and extract standard models, then correlation analyses will be performed between these molecular biological features and multi-dimensional clinical data in order to integrate kp metabonomics, core clinical characteristics (depressed mood, energy loss, interest loss and so on), neuroimaging biomarkers, and finally construct the deep learning based standard diagnostic technique of mdd. additionally, this project will follow up mdd patients with different core clinical characteristics to certificate the aforementioned diagnostic technique as well as explore optimized treatment for different clinical subtypes.


Eligibility criteria:
inclusion criteria: 1. 18-60 years old; 2. meeting with the criteria of major depressive disorder in the diagnostic and statistical manual of mental disorders (dsm)-5; 3. scored 20 or higher on the hamilton's depression scale with 24 items (hamd-24); 4. with enough audio-visual ability and comprehensive ability to accomplish the visits; 5. be necessary and suitable to accept the treatment of antidepressants; 6. scored less than 14 on hamilton's anxiety scale (hama) and scored less than 14 on the hypomania symptom checklist-32 (hcl-32); 7. with 2 or more atypical symptoms including significant weight gain or increase in appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal rejection sensitivity that results in significant social or occupational impairment. exclusion criteria: 1. severe medical or neurological problems; 2. previous mania or hypomania episodes; 3. female patients who are pregnant, planning to be pregnant or breastfeeding; 4. actively suicide ascertained by research psychiatrist or 3rd item of hamd scored≥3(suicidality); 5. had electroconvulsive therapy, modified electroconvulsive therapy or repetitive transcranial magnetic stimulation in the past 6 months; 6. experienced severe personality disorder, mental retardation, anorexia/bulimia nervosa.
taboo perception of incontinence, depression and cancer

Conditions: Urinary Incontinence Awareness; Gender Differences

Summary: objective/study hypothesis to evaluate how much of a taboo ui is and how it compares to other medical conditions that may also pose a taboo issue like depression and cancer. background urinary incontinence (ui) is a highly prevalent condition with more than 200 million people worldwide being affected. while physical health does not necessarily have to be impaired much, restriction of social activities leads to isolation, a significant reduction in quality of life and will often bring about subsequent morbidity. despite its prevalence, many patients suffering from ui go undiagnosed and untreated. patients often hesitate to report the problem, and health care professionals often do not ask about it. in a study minassian (2003) estimated that just one in four patients actively seeks medical attention. the reason for this may lie in the shame, embarrassment, and stigma associated with this condition, which in turn pose significant barriers to seeking professional treatment. although mentioned by many narrative reviews and included in some epidemiological papers on ui, surprisingly we found no data addressing the taboo of ui exclusively. the aim of our study therefore was methods/design a 13-question self-administered questionnaire was developed and face validity tested by 2 of the authors (kh, eh). the anonymous questionnaire contained simple questions on gender and age and then asked yes/no questions on whether test persons knew people with ui, or suspected other people to be incontinent, if they would address this issue with the suspected person, and if they thought that ui was a taboo issue in the society. on a scale from 0 - 10 they were then asked to grade the amount of embarrassment and anxiety if they themselves were incontinent, compared to depression or cancer. a few questions on knowledge of the condition of ui and to whom test persons would turn to in case of ui concluded the short questionnaire, which took about 5 minutes to fill in. a convenience sample of 150 test persons from waiting areas of a teaching hospital and in private practices of general practitioners in austria agreed to take part in the study, with an additional 10 persons (6.2%) declining after being informed about the subject. data were analysed with the spss 10.0.5 software package using the u-test, chi-square-test, yates-correction, fisher's exact test and kolmogorov-smirnov normality test where appropriate.


Eligibility criteria:
inclusion criteria: - subjects older than 18 years willing to take part in study mentally capable to understand and fill in anonymous questionnaire exclusion criteria: - incomplete questionnaire

Keywords: incontinence urinary taboo shame embarrassment treatment depression cancer
evaluation of the benefits of bilateral fitting in bahs users

Conditions: Bilateral Hearing Loss

Summary: the purpose of this study is to evaluate the benefit of bilateral implantation with bone-anchored hearing systems (bahs), in terms of sound localization abilities, as well as auditory working memory. the hypothesis is that the use of two bahs (bilateral condition) will not only improve localization abilities, but it will also increase the ability to retain words in working memory, compared to performance with only one bahs (unilateral condition).

the patients included in this study are adult patients with a bilateral conductive or mixed hearing loss, that are already bilaterally implanted with two percutaneous bone-anchored devices (bahs). the study consists of two visits. at visit 1, the patients are fitted unilaterally and bilaterally with the investigational device (ponto 3 superpower). after fitting, the patients perform a test of spatial resolution (minimum audible angle, visit 1) and an auditory working memory test (visit 2). these two outcome measures are conducted in the laboratory using the ponto 3 superpower unilaterally and bilaterally. additionally, the patients fill in a questionnaire (ssq12) to report perceived performance in their everyday life with their own devices. this is a post market study and all products used are ce marked and used in clinical practice worldwide.

Eligibility criteria:
inclusion criteria: * adult bahs users, minimum 18 years and maximum 75 years. * native english speakers. * patients that are already bilaterally implanted. * patients with a bilateral conductive or mixed conductive-sensorineural hearing loss. * experience with bilateral ponto of at least 6 months. * patients that are using both their sound processors daily. * pta bc (at 0.5, 1, 2, 3 khz) on both sides lower or equal to 65 db hl. * if the masked bc is available on the patient's journal, the average difference in masked bc (at 0.5, 1, 2, 4 khz) between l and r ear should be lower than 15 db. * if the masked bc is not available on the patient's journal, the average difference in unmasked bc (at 0.5, 1, 2, 4 khz) between l and r ear should be lower than 15 db. exclusion criteria: * not deemed suited by the principal investigator. * if the physician assesses that the patient is not fit for trial participation at any stage. * audiogram at 1st visit shows too large masked bc thresholds (pta bc - at 0.5, 1, 2, 3 khz - on either side larger than 65 db hl). * audiogram at 1st visit shows asymmetric masked bc thresholds (average difference in masked bc - at 0.5, 1, 2, 4 khz - between l and r ear larger or equal to 15 db).

Keywords: bone anchored hearing systems bahs bilateral benefit ponto 3 superpower minimum audible angle auditory working memory